STUDY OF EPIRUBICIN (PHARMORUBICIN®), CARBOPLATIN (PARAPLATIN®) AND CAPECITABINE (XELODA®) (ECC) IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION CANCER WITH PHARMACOGENETIC CORRELATES: